Precision Oncology Unleashed: How Moderna’s mRNA Neoantigen Vaccine Is Rewriting Cancer Care
Moderna & Merck’s Phase 3 INTerpath-001 trial shows intismeran autogene plus pembrolizumab improves melanoma survival. Discover how mRNA is reshaping oncology.